Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + ifosfamide + mitomycin
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents—carboplatin, ifosfamide, and mitomycin—used primarily in the treatment of advanced non-small cell lung cancer (NSCLC). - **Carboplatin** is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function. - **Ifosfamide** is an alkylating agent that interferes with DNA replication by forming covalent bonds with DNA bases. - **Mitomycin** (often as mitomycin C) acts as an alkylating agent after enzymatic activation, causing crosslinking of DNA strands and inhibition of DNA synthesis. The combination has been evaluated in phase II clinical trials for patients with progressive or inoperable NSCLC, showing moderate response rates but significant myelosuppression as the main toxicity[1]. The regimen requires careful hematological monitoring due to its potential for bone marrow suppression.
- Other names
- carboplatin plus ifosfamide plus mitomycincarboplatin/ifosfamide/mitomycin
02
Targets
DNA
Beyond the preview
Go deeper on carboplatin + ifosfamide + mitomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + ifosfamide + mitomycin.